// App-Quantinova.ai

SAT0109 : DISTINCT EFFECTS OF METHOTREXATE IN COMBINATION WITH ADALIMUMAB OR ETANERCEPT ACCORDING TO CCP ANTIBODY STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS

Researchers

Presenter

  • M. Greenwood

Principal Investigators

  • M. Shipa

  • M. Ehrenstein

Medical Centers

  • Kings College London, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • anti-CCP antibodies

Drug/Treatment

  • Methotrexate

  • Adalimumab

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved